Cite
HARVARD Citation
Hungria, V. et al. (2021). Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. British journal of haematology. pp. 561-569. [Online].